Washington, DC 20006-5349
HELPLINE
MESOTHELIOMA NEWS
Scroll to find news of interest to you, or search by category. The Mesothelioma Applied Research Foundation covers mesothelioma news for patients and their families. Our write-ups are heavily reliant on peer-reviewed medical research studies with input from mesothelioma experts from around the world but are also accessible to non-medical readers.
CAR-T (Chimeric antigen receptor) cell therapy is a type of immunotherapy that uses a patient’s T cells to attack cancer cells. T cells are white
For patients with MPM (Malignant Pleural Mesothelioma), the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab) as a first-line treatment when combined with
Mesothelioma has often been classified as a cancer that only affects older people, as the average age of diagnosis for pleural is 72 and peritoneal
The Mesothelioma Applied Research Foundation is excited to announce its latest research grant recipients, awarding a total of $300,000. This brings the Foundation’s
At the Mesothelioma Applied Research Foundation, we are guided by the three core pillars that define our purpose: funding groundbreaking research, providing essential treatment support
The phase 3 clinical trial known as BEAT-meso, which combines chemotherapy plus bevacizumab with immunotherapy, has shown an improvement in overall survival (OS) and progression-free
One of the many services that the Meso Foundation offers to patients, caregivers, and the bereaved community is support groups offered over Zoom video conferencing.
In this episode of MesoTV, three patients, two with peritoneal mesothelioma and one with pleural mesothelioma, tell their stories of diagnosis, treatment, subsequent recurrence, and
Get the latest information about mesothelioma, clinical trials, patient stories, community events, and much more!
